var data={"title":"Primary cutaneous T cell lymphomas, rare subtypes","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Primary cutaneous T cell lymphomas, rare subtypes</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/contributors\" class=\"contributor contributor_credentials\">Rein Willemze, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/contributors\" class=\"contributor contributor_credentials\">John A Zic, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 21, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1060059838\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The term primary cutaneous T cell lymphoma (CTCL) refers to T cell lymphomas that present primarily in the skin without evidence of extracutaneous disease at the time of diagnosis. The group of classical CTCLs (mycosis fungoides, variants of mycosis fungoides, and S&eacute;zary's syndrome) and the group of primary cutaneous CD30<sup>+</sup> lymphoproliferative disorders (anaplastic large cell lymphoma and lymphomatoid papulosis) encompass the most common forms of CTCLs, accounting for approximately 90 percent of CTCLs in the Western world [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/1\" class=\"abstract_t\">1</a>]. However, different distributions have been observed in other parts of the world [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/2,3\" class=\"abstract_t\">2,3</a>]. </p><p>Other types of CTCLs recognized in the 2005 World Health Organization (WHO)-European Organization for Research and Treatment of Cancer classification of cutaneous lymphomas [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/1\" class=\"abstract_t\">1</a>] and in the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissue [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/4\" class=\"abstract_t\">4</a>] include uncommon entities such as: subcutaneous panniculitis-like T cell lymphoma; extranodal natural <span class=\"nowrap\">killer/T</span> cell lymphoma, nasal type; primary cutaneous peripheral T cell lymphoma (PTCL), not otherwise specified; and rare subtypes of PTCL [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/1,4\" class=\"abstract_t\">1,4</a>].</p><p>This topic will focus on rare subtypes of primary cutaneous PTCL, which include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary cutaneous gamma-delta T cell lymphoma</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary cutaneous aggressive epidermotropic CD8<sup>+</sup> cytotoxic T cell lymphoma</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary cutaneous acral CD8<sup>+</sup> T cell lymphoma</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary cutaneous CD4<sup>+</sup> <span class=\"nowrap\">small/medium</span> T cell lymphoproliferative disorder</p><p/><p>Mycosis fungoides, S&eacute;zary syndrome, primary cutaneous CD30<sup>+</sup> lymphoproliferative disorders, and other uncommon types of CTCL are discussed separately. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-mycosis-fungoides\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=clinical-presentation-pathologic-features-and-diagnosis-of-sezary-syndrome\" class=\"medical medical_review\">&quot;Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=primary-cutaneous-anaplastic-large-cell-lymphoma\" class=\"medical medical_review\">&quot;Primary cutaneous anaplastic large cell lymphoma&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=lymphomatoid-papulosis\" class=\"medical medical_review\">&quot;Lymphomatoid papulosis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-subcutaneous-panniculitis-like-t-cell-lymphoma\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T cell lymphoma&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-extranodal-nk-t-cell-lymphoma-nasal-type\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H3215520080\"><span class=\"h1\">PRIMARY CUTANEOUS GAMMA-DELTA T CELL LYMPHOMA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary cutaneous gamma-delta T cell lymphoma (PCGD-TCL) is a rare lymphoma composed of a clonal proliferation of mature, activated gamma-delta T cells with a cytotoxic phenotype and characterized by rapid progression and poor prognosis [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/5\" class=\"abstract_t\">5</a>]. This group includes cases previously known as subcutaneous panniculitis-like T cell lymphoma (SPTCL) with a gamma-delta phenotype.</p><p class=\"headingAnchor\" id=\"H977111405\"><span class=\"h2\">Epidemiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PCGD-TCL is rare, representing approximately 1 percent of all cutaneous T cell lymphomas (CTCLs) [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/1\" class=\"abstract_t\">1</a>]. Most patients are adults, with a median age of approximately 60 years (range 25 to 91) [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/5\" class=\"abstract_t\">5</a>].</p><p class=\"headingAnchor\" id=\"H511037125\"><span class=\"h2\">Pathogenesis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Consistent with the prevalence of V-delta-2 gamma-delta T cells in the skin, the tumor cells of PCGD-TCL usually express V-delta-2 [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/6,7\" class=\"abstract_t\">6,7</a>]. Since V-delta-2 gamma-delta T cells may act as antigen-presenting cells, chronic antigenic stimulation is thought to play a role in the pathogenesis of PCGD-TCL [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/6,7\" class=\"abstract_t\">6,7</a>].</p><p class=\"headingAnchor\" id=\"H2652089255\"><span class=\"h2\">Clinical features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PCGD-TCL usually presents with disseminated, rapidly progressing plaques <span class=\"nowrap\">and/or</span> ulceronecrotic nodules or tumors, preferentially located on the extremities (<a href=\"image.htm?imageKey=DERM%2F109196\" class=\"graphic graphic_picture graphicRef109196 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/8,9\" class=\"abstract_t\">8,9</a>]. Mucosal and other extranodal sites are frequently involved, but involvement of lymph nodes, spleen, or bone marrow is uncommon. PCGD-TCL may be associated with a hemophagocytic syndrome, particularly in patients with panniculitis-like tumors [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/8,9\" class=\"abstract_t\">8,9</a>]. B symptoms, including fever, night sweats, and weight loss, are seen in most patients. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-hemophagocytic-lymphohistiocytosis\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of hemophagocytic lymphohistiocytosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2462217364\"><span class=\"h2\">Pathology</span></p><p class=\"headingAnchor\" id=\"H3552705443\"><span class=\"h3\">Morphology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In contrast with SPTCL, the neoplastic infiltrates of PCGD-TCL are not confined to the subcutaneous tissue but generally involve the epidermis <span class=\"nowrap\">and/or</span> dermis as well [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/8,9\" class=\"abstract_t\">8,9</a>]. Epidermal infiltration may occur as mild epidermotropism to marked pagetoid reticulosis-like infiltrates, which may be associated with intraepidermal vesiculation and necrosis. Angiocentricity, angiodestruction, and tissue necrosis are common. The neoplastic cells are generally medium to large in size with coarsely clumped chromatin (<a href=\"image.htm?imageKey=DERM%2F109197\" class=\"graphic graphic_picture graphicRef109197 \">picture 2</a>).</p><p class=\"headingAnchor\" id=\"H4002759965\"><span class=\"h3\">Immunophenotype</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The neoplastic cells of PCGD-TCL characteristically have a T cell receptor (TCR)-gamma<sup>+</sup>, beta-F1<sup>-</sup>, CD3<sup>+</sup>, CD2<sup>+</sup>, CD5<sup>-</sup>, CD4<sup>-</sup>, CD8<sup>-</sup>, CD56<sup>+</sup> phenotype with strong expression of cytotoxic proteins (<a href=\"image.htm?imageKey=DERM%2F109198\" class=\"graphic graphic_picture graphicRef109198 \">picture 3</a>) [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/7-10\" class=\"abstract_t\">7-10</a>]. Coexpression of TCR-gamma and beta-F1 has been reported in some cases [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/11\" class=\"abstract_t\">11</a>]. Epstein-Barr virus is negative.</p><p class=\"headingAnchor\" id=\"H2076779603\"><span class=\"h3\">Genetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most cases of PCGD-TCL show clonally rearranged TCR and TCR-delta<em> </em>genes. No other genetic features have been reported.</p><p class=\"headingAnchor\" id=\"H3359917847\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of PCGD-TCL requires the integration of clinical, histologic, phenotypic, and molecular genetic data. Deep punch biopsies (&ge;4 mm) or incisional biopsies can be performed for routine histopathology, immunophenotyping, and molecular analysis. New commercially available TCR-gamma antibodies have been extremely helpful in differentiating between PCGD-TCL and other aggressive primary CTCLs with a cytotoxic T cell phenotype. However, it should be noted that TCR-gamma expression is found not only in PCGD-TCL but also in other types of CTCLs, including rare cases of otherwise classical mycosis fungoides (MF) and lymphomatoid papulosis type D [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/11,12\" class=\"abstract_t\">11,12</a>]. </p><p class=\"headingAnchor\" id=\"H615099160\"><span class=\"h2\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of PCGD-TCL includes:</p><p class=\"headingAnchor\" id=\"H2308806457\"><span class=\"h3\">Subcutaneous panniculitis-like T cell lymphoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Both PCGD-TCL and SPTCL may present on histopathologic examination as nodular lesions with panniculitis-like features with rimming of fat cells (<a href=\"image.htm?imageKey=HEME%2F82054\" class=\"graphic graphic_picture graphicRef82054 \">picture 4</a>). In contrast to SPTCL, PCGD-TCL commonly involves not only the subcutis but also the dermis <span class=\"nowrap\">and/or</span> epidermis, either in the same biopsy or in different biopsies of lesional skin, and may show ulceration. </p><p>While SPTCL has an alpha-beta T cell phenotype, PCGD-TCL has a gamma-delta T cell phenotype, is generally negative for both CD4 and CD8, and commonly expresses CD56 (<a href=\"image.htm?imageKey=DERM%2F109199\" class=\"graphic graphic_table graphicRef109199 \">table 1</a>). The differentiation of these two entities is important, since PCGD-TCL with panniculitis-like features generally has a poor prognosis and requires systemic combination chemotherapy [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/8,9\" class=\"abstract_t\">8,9</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-subcutaneous-panniculitis-like-t-cell-lymphoma\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T cell lymphoma&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1823462876\"><span class=\"h3\">Mycosis fungoides</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The histopathologic differentiation of PCGD-TCL from tumor-stage MF and, uncommonly, plaque-stage MF may be difficult. Clinicopathologic correlation is essential. While the neoplastic T cells in MF have TCR-gamma<sup>-</sup>, beta-F1<sup>+</sup>, CD4<sup>+</sup>, or, less commonly, a CD8<sup>+</sup> T cell phenotype, the T cells in PCGD-TCL have a TCR-gamma<sup>+</sup>, beta-F1<sup>-</sup>, CD4<sup>-</sup>, CD8<sup>-</sup> T cell phenotype. However, rare cases of otherwise classical MF expressing TCR-gamma have been reported [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/11,12\" class=\"abstract_t\">11,12</a>]. Documentation of previous or concurrent presence of patch or plaque-like lesions strongly suggests a diagnosis of MF. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-mycosis-fungoides\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2930919974\"><span class=\"h2\">Treatment and prognosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Because of its rarity, there are no randomized trials addressing the treatment of PCGD-TCL. These patients should be treated with combination chemotherapy using the regimens suggested for peripheral T cell lymphoma, not otherwise specified (PTCL, NOS). Pretreatment evaluation, initial treatment, and treatment of PTCL, NOS are presented elsewhere. (See <a href=\"topic.htm?path=initial-treatment-of-peripheral-t-cell-lymphoma\" class=\"medical medical_review\">&quot;Initial treatment of peripheral T cell lymphoma&quot;</a> and <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory peripheral T cell lymphoma&quot;</a>.)</p><p>PCGD-TCL usually has an aggressive clinical course, is resistant to multiagent chemotherapy, and has a poor prognosis, with a median survival of approximately 15 months [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/8,9\" class=\"abstract_t\">8,9</a>]. Patients with subcutaneous fat involvement tend to have a poorer prognosis than patients with epidermal or dermal disease only [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/9\" class=\"abstract_t\">9</a>]. Rare cases of PCGD-TCL following a more indolent clinical course have been reported [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/5,13,14\" class=\"abstract_t\">5,13,14</a>].</p><p class=\"headingAnchor\" id=\"H3966910172\"><span class=\"h1\">PRIMARY CUTANEOUS CD8+ AGGRESSIVE EPIDERMOTROPIC CYTOTOXIC T CELL LYMPHOMA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary cutaneous CD8<sup>+</sup> aggressive epidermotropic cytotoxic T cell lymphoma (AECTCL) is a rare cutaneous lymphoma characterized by a proliferation of epidermotropic CD8<sup>+</sup> cytotoxic T cells, an aggressive clinical behavior, and poor prognosis [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/15\" class=\"abstract_t\">15</a>]. CD8<sup>+</sup> AECTCL is included as a provisional entity in the 2005 World Health Organization (WHO)-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas and in the 2016 revision of the WHO classification of hematopoietic neoplasms [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/1,4\" class=\"abstract_t\">1,4</a>].</p><p class=\"headingAnchor\" id=\"H286944658\"><span class=\"h2\">Epidemiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CD8<sup>+</sup> AECTCL is rare, representing approximately 1 percent of all cutaneous T cell lymphomas (CTCL) [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/1\" class=\"abstract_t\">1</a>]. Most patients are adults. </p><p class=\"headingAnchor\" id=\"H2670051392\"><span class=\"h2\">Clinical features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with CD8<sup>+</sup> AECTCL present with localized or disseminated eruptive papules, nodules, and tumors showing central ulceration and necrosis (<a href=\"image.htm?imageKey=DERM%2F109201\" class=\"graphic graphic_picture graphicRef109201 \">picture 5</a>) or with superficial, hyperkeratotic patches and plaques [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/15-17\" class=\"abstract_t\">15-17</a>]. CD8<sup>+</sup> AECTCL progresses rapidly over weeks to months and shows a propensity to disseminate to visceral sites such as the lung, testis, central nervous system, and oral mucosa, but lymph nodes are often spared [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/15,17\" class=\"abstract_t\">15,17</a>].</p><p class=\"headingAnchor\" id=\"H2042083201\"><span class=\"h2\">Pathology</span></p><p class=\"headingAnchor\" id=\"H340985578\"><span class=\"h3\">Morphology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The histopathologic appearance of CD8<sup>+</sup> AECTCL is variable, ranging from a lichenoid pattern with marked, pagetoid epidermotropism and subepidermal edema in early patch-like lesions to diffuse dermal infiltrates in nodular and tumor-like lesions (<a href=\"image.htm?imageKey=DERM%2F109202\" class=\"graphic graphic_picture graphicRef109202 \">picture 6</a>). Epidermal necrosis and ulceration as well as invasion and destruction of adnexal skin structures are commonly found [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/15-18\" class=\"abstract_t\">15-18</a>]. Angiocentricity and angioinvasion may be present. Tumor cells are small-medium or medium-large with pleomorphic or blastic nuclei.</p><p class=\"headingAnchor\" id=\"H459311579\"><span class=\"h3\">Immunophenotype</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The neoplastic T cells of CD8<sup>+</sup> AECTCL have a beta-F1<sup>+</sup>, CD3<sup>+</sup>, CD8<sup>+</sup>, granzyme B<sup>+</sup>, perforin<sup>+</sup>, TIA-1<sup>+</sup>, CD45RA<sup><span class=\"nowrap\">+/-</sup>,</span> CD45RO<sup>-</sup>, CD2<sup><span class=\"nowrap\">-/+</sup>,</span> CD4<sup>-</sup>, CD5<sup>-</sup>, CD7<sup><span class=\"nowrap\">+/-</sup></span> phenotype (<a href=\"image.htm?imageKey=DERM%2F109207\" class=\"graphic graphic_picture graphicRef109207 \">picture 7</a>) [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/15-17\" class=\"abstract_t\">15-17</a>]. CD30 is rarely expressed [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/17,19\" class=\"abstract_t\">17,19</a>]. Epstein-Barr virus is negative [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/17,20\" class=\"abstract_t\">17,20</a>].</p><p class=\"headingAnchor\" id=\"H3963980722\"><span class=\"h3\">Genetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The neoplastic T cells of CD8<sup>+</sup> AECTCL show clonal T cell receptor gene rearrangements. Specific genetic abnormalities have not been described.</p><p class=\"headingAnchor\" id=\"H304736455\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of CD8<sup>+</sup> AECTCL is based upon the combination of the clinical, histopathologic, and immunophenotypic findings described above. Deep punch biopsies (&ge;4 mm) or incisional biopsies can be performed for routine histopathology, immunophenotyping, and molecular analysis. Since several types of primary CTCLs express a CD8<sup>+</sup> cytotoxic T cell phenotype (<a href=\"image.htm?imageKey=DERM%2F109206\" class=\"graphic graphic_table graphicRef109206 \">table 2</a>), a careful clinicopathologic correlation is key to the correct diagnosis [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/19,21\" class=\"abstract_t\">19,21</a>].</p><p class=\"headingAnchor\" id=\"H3129258417\"><span class=\"h2\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of CD8<sup>+</sup> AECTCL includes several subtypes of CTCL that show infiltration of CD8<sup>+ </sup>T neoplastic T cells (<a href=\"image.htm?imageKey=DERM%2F109206\" class=\"graphic graphic_table graphicRef109206 \">table 2</a>).</p><p class=\"headingAnchor\" id=\"H2956283695\"><span class=\"h3\">Lymphomatoid papulosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lymphomatoid papulosis (LyP) type D is a newly described histologic subtype of LyP that shows the same histologic and immunophenotypic characteristics as CD8<sup>+</sup> AECTCL [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/22\" class=\"abstract_t\">22</a>]. However, in contrast with CD8<sup>+</sup> AECTCL, LyP type D has a clinical indolent behavior characterized by the recurrence of self-healing papulonecrotic lesions limited to the skin, without involvement of extracutaneous sites. (See <a href=\"topic.htm?path=lymphomatoid-papulosis\" class=\"medical medical_review\">&quot;Lymphomatoid papulosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H227044828\"><span class=\"h3\">Primary cutaneous anaplastic large cell lymphoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) usually shows a CD4<sup>+</sup> CD30<sup>+</sup> T cell phenotype, but in rare instances it may express CD8 [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/23\" class=\"abstract_t\">23</a>]. In contrast with CD8<sup>+</sup> AECTCL, which in most cases presents with multiple disseminated lesions, PC-ALCL usually presents with a solitary or a few clustered skin lesions. Rare cases of CTCL showing coexpression of CD8 and CD30 most likely belong to the spectrum of primary cutaneous CD30<sup>+</sup> lymphoproliferative disorders, although CD8<sup>+</sup> AECTCL may occasionally also express CD30 [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/17,19\" class=\"abstract_t\">17,19</a>]. (See <a href=\"topic.htm?path=primary-cutaneous-anaplastic-large-cell-lymphoma\" class=\"medical medical_review\">&quot;Primary cutaneous anaplastic large cell lymphoma&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3313974397\"><span class=\"h3\">Mycosis fungoides</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Early lesions of CD8<sup>+</sup> AECTCL should be differentiated from patch- or plaque-stage mycosis fungoides (MF). Although in most cases MF has a CD4<sup>+</sup>, CD8<sup>-</sup> T cell phenotype, approximately 15 percent of cases of <span class=\"nowrap\">early-patch/plaque-stage</span> MF show a CD4<sup>-</sup>, CD8<sup>+</sup> T cell phenotype with strong expression of cytotoxic proteins [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/24\" class=\"abstract_t\">24</a>]. Differentiating CD8<sup>+</sup> AECTCL from rare cases of CD8<sup>+</sup> tumor-stage MF, which may also present with ulcerating tumors, is much more difficult. Clinical and histopathologic documentation of previous or concurrent patch or plaque lesions is essential for a correct diagnosis. Strong expression of CD30 in such cases argues against a diagnosis of CD8<sup>+</sup> AECTCL [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/19\" class=\"abstract_t\">19</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-mycosis-fungoides\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2206975216\"><span class=\"h3\">Pagetoid reticulosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>On histology, early lesions of CD8<sup>+</sup> AECTCL that show marked pagetoid epidermotropism of neoplastic CD8<sup>+</sup> cytotoxic T cells may closely resemble pagetoid reticulosis, a rare variant of MF characterized by intraepidermal proliferation of neoplastic T cells. Pagetoid reticulosis typically presents with a slowly progressive psoriasiform or hyperkeratotic patch or plaque at the distal extremities. Unlike CD8<sup>+</sup> AECTCL, the neoplastic T cells in pagetoid reticulosis may have either a CD4<sup>+</sup>, CD8<sup>-</sup> or a CD4<sup>-</sup>, CD8<sup>+</sup> T cell phenotype and often express CD30 [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/25,26\" class=\"abstract_t\">25,26</a>].</p><p class=\"headingAnchor\" id=\"H339129503\"><span class=\"h3\">Subcutaneous panniculitis-like T cell lymphoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Subcutaneous panniculitis-like T cell lymphoma (SPTCL) presents with nodular skin lesions most often located on the legs. The neoplastic T cells express CD8 and the cytotoxic proteins TIA-1, granzyme B, and perforin. However, in contrast with CD8<sup>+</sup> AECTCL, the infiltrates of SPTCL are restricted to the subcutis, and epidermotropism is absent [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/8\" class=\"abstract_t\">8</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-subcutaneous-panniculitis-like-t-cell-lymphoma\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T cell lymphoma&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H3568978086\"><span class=\"h3\">Primary cutaneous acral CD8+ T cell lymphoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The main differences between primary cutaneous acral CD8<sup>+</sup> T cell lymphoma and tumor-like lesions of CD8<sup>+</sup> AECTCL include the presence of a solitary lesion at acral sites (particularly the ears), an indolent clinical behavior, lack of epidermotropism, and low proliferation rate. (See <a href=\"#H646240243\" class=\"local\">'Primary cutaneous acral CD8+ T cell lymphoma'</a> below.)</p><p class=\"headingAnchor\" id=\"H652721910\"><span class=\"h2\">Treatment and prognosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Because of its rarity, there are no randomized trials addressing the treatment of CD8<sup>+</sup> AECTCL. Patients are usually treated with combination chemotherapy, using the regimens for peripheral T cell lymphoma (PTCL), not otherwise specified. Pretreatment evaluation, initial treatment, and treatment of relapsed or refractory PTCL are presented elsewhere. (See <a href=\"topic.htm?path=initial-treatment-of-peripheral-t-cell-lymphoma\" class=\"medical medical_review\">&quot;Initial treatment of peripheral T cell lymphoma&quot;</a> and <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory peripheral T cell lymphoma&quot;</a>.)</p><p>The clinical course of CD8<sup>+</sup> AECTCL is aggressive, and the response to chemotherapy is often disappointing. The reported median survival is less than two years [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/15-17\" class=\"abstract_t\">15-17</a>]. </p><p class=\"headingAnchor\" id=\"H646240243\"><span class=\"h1\">PRIMARY CUTANEOUS ACRAL CD8+ T CELL LYMPHOMA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary cutaneous acral CD8<sup>+</sup> T cell lymphoma is a newly described entity histologically characterized by a diffuse infiltrate of medium-sized CD8<sup>+</sup> cytotoxic T cells suggesting a high-grade malignant lymphoma and an indolent clinical behavior [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/27\" class=\"abstract_t\">27</a>]. This condition, initially designated &quot;indolent CD8-positive lymphoid proliferation of the ear,&quot; has been included as a provisional entity in the 2016 revision of the World Health Organization classification [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/4\" class=\"abstract_t\">4</a>].</p><p class=\"headingAnchor\" id=\"H4206581917\"><span class=\"h2\">Epidemiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary cutaneous acral CD8<sup>+</sup> T cell lymphoma is rare. It has been reported only in adults and shows a male predominance.</p><p class=\"headingAnchor\" id=\"H3773574672\"><span class=\"h2\">Clinical features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with primary cutaneous acral CD8<sup>+</sup> T cell lymphoma typically present with a solitary, slowly progressive papule or nodule, most commonly located on the ear (<a href=\"image.htm?imageKey=DERM%2F109234\" class=\"graphic graphic_picture graphicRef109234 \">picture 8</a>). Similar lesions may occur at other acral sites including the nose and the foot [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/27-31\" class=\"abstract_t\">27-31</a>]. In rare cases, both ears or feet may be affected [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/27,30-33\" class=\"abstract_t\">27,30-33</a>]. One report describes a patient with recurrent and multifocal lesions on several acral sites [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/31\" class=\"abstract_t\">31</a>].</p><p class=\"headingAnchor\" id=\"H1390843739\"><span class=\"h2\">Pathology</span></p><p class=\"headingAnchor\" id=\"H1613636157\"><span class=\"h3\">Morphology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The lesions of primary cutaneous acral CD8<sup>+</sup> T cell lymphoma show a diffuse proliferation of monomorphous, medium-sized blast cells throughout the dermis and subcutis, separated from the epidermis by a clear grenz zone (<a href=\"image.htm?imageKey=DERM%2F109235\" class=\"graphic graphic_picture graphicRef109235 \">picture 9</a>) [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/27\" class=\"abstract_t\">27</a>].</p><p class=\"headingAnchor\" id=\"H3697945490\"><span class=\"h3\">Immunophenotype</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The tumor cells have a CD3<sup>+</sup>, CD4<sup>-</sup>, CD8<sup>+</sup>, TIA-1<sup>+</sup>, granzyme B<sup>-</sup>, CD30<sup>-</sup> T cell phenotype (<a href=\"image.htm?imageKey=DERM%2F109235\" class=\"graphic graphic_picture graphicRef109235 \">picture 9</a>) [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/27,30\" class=\"abstract_t\">27,30</a>]. CD68 often shows a positive Golgi dot-like staining [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/33\" class=\"abstract_t\">33</a>]. Loss of pan-T cell antigens (CD2, CD5, CD7) may occur. In almost all cases, the proliferation rate is very low (&lt;10 percent). Epstein-Barr virus is negative.</p><p class=\"headingAnchor\" id=\"H1567064775\"><span class=\"h3\">Genetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The neoplastic T cells of primary cutaneous acral CD8<sup>+</sup> T cell lymphoma show clonal T cell receptor gene rearrangements. Specific genetic abnormalities have not been described.</p><p class=\"headingAnchor\" id=\"H2411723022\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of primary cutaneous acral CD8<sup>+</sup> T cell lymphoma is based upon the finding of a solitary, slowly growing papule or nodule on the ear or other acral site that demonstrates on histopathologic examination a diffuse proliferation of monomorphous CD8<sup>+</sup> medium-sized blast cells. An excisional biopsy can be performed for lesions that are small (&lt;2 cm) and well demarcated. For larger lesions, deep punch biopsies (&ge;4 mm) or incisional biopsies are appropriate for diagnosis. In contrast with aggressive CD8<sup>+</sup> primary cutaneous T cell lymphoma, the proliferation rate is typically low.</p><p class=\"headingAnchor\" id=\"H2834565175\"><span class=\"h2\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of primary cutaneous acral CD8<sup>+</sup> T cell lymphoma includes benign and malignant lesions that may also present with a solitary papule or nodule on the ears, nose, or other acral sites. These include, among others, primary cutaneous follicle center lymphoma, folliculotropic mycosis fungoides, and, in particular, cutaneous B cell pseudolymphomas (<a href=\"image.htm?imageKey=DERM%2F103721\" class=\"graphic graphic_picture graphicRef103721 \">picture 10</a>). However, the demonstration of a diffuse proliferation of CD8<sup>+</sup> T cells on histopathologic examination suggests the correct diagnosis. (See <a href=\"topic.htm?path=cutaneous-b-cell-pseudolymphomas\" class=\"medical medical_review\">&quot;Cutaneous B cell pseudolymphomas&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2580171248\"><span class=\"h2\">Treatment and prognosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Surgical excision or radiotherapy usually results in complete remission. Relapses may occur and are often localized at the same acral site [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/30\" class=\"abstract_t\">30</a>]. The recognition that these lesions have an indolent clinical behavior, despite an aggressive histology, is important to prevent unnecessarily aggressive treatment.</p><p>The prognosis of primary cutaneous acral CD8<sup>+</sup> T cell lymphoma is excellent [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/27,30\" class=\"abstract_t\">27,30</a>]. </p><p class=\"headingAnchor\" id=\"H622037723\"><span class=\"h1\">PRIMARY CUTANEOUS CD4+ SMALL/MEDIUM T CELL LYMPHOPROLIFERATIVE DISORDER</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the 2005 World Health Organization (WHO)-European Organization for Research and Treatment of Cancer classification of cutaneous lymphomas and in the WHO 2008 classification, primary cutaneous CD4<sup>+</sup> <span class=\"nowrap\">small/medium</span> T cell lymphoma was included as a provisional type of primary cutaneous T cell lymphoma (CTCL), defined by a predominance of small- to medium-sized CD4<sup>+</sup> pleomorphic T cells without prior or concurrent patches and plaques typical of mycosis fungoides (MF) [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/1,34\" class=\"abstract_t\">1,34</a>]. It has been recognized that cases presenting with a solitary plaque or tumor have the same clinicopathologic and immunophenotypic features and the same benign clinical course as cutaneous T cell pseudolymphomas with a nodular growth pattern [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/35-37\" class=\"abstract_t\">35-37</a>] (see <a href=\"topic.htm?path=cutaneous-t-cell-pseudolymphomas#H373512131\" class=\"medical medical_review\">&quot;Cutaneous T cell pseudolymphomas&quot;, section on 'Idiopathic (solitary) T cell pseudolymphoma'</a>). In the 2016 revision of the WHO classification, the term &quot;primary cutaneous CD4<sup>+</sup> <span class=\"nowrap\">small/medium</span> T cell lymphoproliferative disorder&quot; is therefore preferred [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/4\" class=\"abstract_t\">4</a>].</p><p class=\"headingAnchor\" id=\"H324713509\"><span class=\"h2\">Epidemiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary cutaneous CD4<sup>+</sup> <span class=\"nowrap\">small/medium</span> T cell lymphoproliferative disorder is a rare disease, accounting for 2 to 3 percent of all CTCL [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H3348273444\"><span class=\"h2\">Clinical features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients with primary cutaneous CD4<sup>+</sup> <span class=\"nowrap\">small/medium</span> T cell lymphoproliferative disorder typically present with a solitary plaque or tumor, generally on the face, the neck, or the upper trunk (<a href=\"image.htm?imageKey=DERM%2F103522\" class=\"graphic graphic_picture graphicRef103522 \">picture 11</a>) [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/35,36,38-41\" class=\"abstract_t\">35,36,38-41</a>]. Generalized skin lesions are a much less common presentation [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/35,36\" class=\"abstract_t\">35,36</a>]. </p><p>Rare cases presenting with generalized skin lesions and large, rapidly growing tumors showing on histopathology more than 30 percent large pleomorphic T cells <span class=\"nowrap\">and/or</span> a high proliferative fraction do not belong to this group [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/38,39\" class=\"abstract_t\">38,39</a>]. Such cases usually have a more aggressive clinical behavior and should be classified as peripheral T cell lymphoma, not otherwise specified (PTCL, NOS). (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-peripheral-t-cell-lymphoma-not-otherwise-specified\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2139991237\"><span class=\"h2\">Pathologic features</span></p><p class=\"headingAnchor\" id=\"H1494371565\"><span class=\"h3\">Morphology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>On histopathologic examination, primary cutaneous CD4<sup>+</sup> <span class=\"nowrap\">small/medium</span> T cell lymphoproliferative disorder is identical to idiopathic (solitary) T cell pseudolymphoma with a nodular growth pattern (<a href=\"image.htm?imageKey=DERM%2F103537\" class=\"graphic graphic_picture graphicRef103537 \">picture 12</a>) [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/35-37\" class=\"abstract_t\">35-37</a>]. (See <a href=\"topic.htm?path=cutaneous-t-cell-pseudolymphomas#H373512131\" class=\"medical medical_review\">&quot;Cutaneous T cell pseudolymphomas&quot;, section on 'Idiopathic (solitary) T cell pseudolymphoma'</a>.)</p><p>These lesions show dense, nodular to diffuse infiltrates within the dermis, with a tendency to infiltrate the subcutis. There is a predominance of <span class=\"nowrap\">small-/medium-sized</span> pleomorphic T cells; epidermotropism is generally mild or absent [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/35,36,38-40\" class=\"abstract_t\">35,36,38-40</a>]. A small proportion (&lt;30 percent) of large pleomorphic cells may be present [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/20\" class=\"abstract_t\">20</a>]. In almost all cases, there is a considerable admixture with small reactive CD8<sup>+</sup> T cells, B cells, and histiocytes including multinucleated giant cells [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/35,36,40\" class=\"abstract_t\">35,36,40</a>]. Eosinophils are generally few or absent.</p><p class=\"headingAnchor\" id=\"H1865940484\"><span class=\"h3\">Immunophenotype</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>By definition, primary cutaneous CD4<sup>+</sup> <span class=\"nowrap\">small/medium</span> T cell lymphoproliferative disorder has a CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>-</sup>, CD30<sup>-</sup> phenotype, similar to idiopathic T cell pseudolymphoma <span class=\"nowrap\">(nodular/diffuse</span> type). Loss of pan-T cell markers is uncommon, and cytotoxic proteins are not expressed [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/35,36,38,40\" class=\"abstract_t\">35,36,38,40</a>]. Several studies showed that the medium-sized to large atypical CD4<sup>+</sup> T cells consistently express the follicular helper T cell markers PD-1, BCL6, and CXCL13 but (unlike angioimmunoblastic T cell lymphoma) not CD10 (<a href=\"image.htm?imageKey=DERM%2F103538\" class=\"graphic graphic_picture graphicRef103538 \">picture 13</a>) [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/36,40\" class=\"abstract_t\">36,40</a>]. The proliferation rate is low, varying between less than 5 percent and at most 20 percent. Epstein-Barr virus is negative.</p><p class=\"headingAnchor\" id=\"H1334410468\"><span class=\"h3\">Genetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clonal T cell receptor gene rearrangements are detected in most cases [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/36,40\" class=\"abstract_t\">36,40</a>]. Specific genetic abnormalities have not been described.</p><p class=\"headingAnchor\" id=\"H2031985525\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of primary cutaneous CD4<sup>+</sup> <span class=\"nowrap\">small/medium</span> T cell lymphoproliferative disorder is based upon the clinical finding of a solitary plaque or nodule on the face or trunk that demonstrates the histopathologic and immunophenotypic features described above. An excisional biopsy can be performed for lesions that are small (&lt;2 cm) and well demarcated. For larger lesions, deep punch biopsies (&ge;4 mm) or incisional biopsies are appropriate for diagnosis. A careful clinicopathologic correlation is necessary for a correct diagnosis. </p><p class=\"headingAnchor\" id=\"H4285820249\"><span class=\"h2\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of primary cutaneous CD4<sup>+</sup> <span class=\"nowrap\">small/medium</span> T cell lymphoproliferative disorder includes tumor stage MF and primary cutaneous PTCL, NOS. </p><p>The presence of scattered medium-sized to large CD4<sup>+</sup> T cells expressing PD-1, many admixed B cells, CD8<sup>+</sup> T cells, and histiocytes and the low proliferation rate are useful criteria to differentiate this condition from MF and primary cutaneous PTCL, NOS [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/36,42\" class=\"abstract_t\">36,42</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-mycosis-fungoides#H14\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides&quot;, section on 'Morphology'</a> and <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-peripheral-t-cell-lymphoma-not-otherwise-specified#H4\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified&quot;, section on 'Pathology'</a>.) </p><p class=\"headingAnchor\" id=\"H1409425915\"><span class=\"h2\">Treatment and prognosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary cutaneous CD4<sup>+</sup> <span class=\"nowrap\">small/medium</span> T cell lymphoproliferative disorder lesions may resolve spontaneously after skin biopsy [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/36,40\" class=\"abstract_t\">36,40</a>]. Persistent lesions can be treated with intralesional steroids, surgical excision, or, in rare instances, with radiotherapy [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/35,36,38\" class=\"abstract_t\">35,36,38</a>].</p><p>Local recurrences after initial treatment are rarely observed. Patients have an excellent long-term prognosis and do not require further examinations or staging [<a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/35,36,38\" class=\"abstract_t\">35,36,38</a>].</p><p class=\"headingAnchor\" id=\"H1566918739\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary cutaneous T cell lymphomas, rare subtypes, is a heterogeneous group of extremely rare T cell lymphomas that present primarily in the skin without evidence of extracutaneous involvement. A careful clinicopathologic correlation is the key to a correct diagnosis. (See <a href=\"#H1060059838\" class=\"local\">'Introduction'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary cutaneous gamma-delta T cell lymphoma (PCGD-TCL) is a rare lymphoma composed of a clonal proliferation of mature, activated gamma-delta T cells with a cytotoxic phenotype. It presents with disseminated plaques <span class=\"nowrap\">and/or</span> ulceronecrotic nodules or tumors preferentially located on the extremities (<a href=\"image.htm?imageKey=DERM%2F109196\" class=\"graphic graphic_picture graphicRef109196 \">picture 1</a>). The neoplastic cells of PCGD-TCL characteristically have a T cell receptor-gamma<sup>+</sup>, beta-F1<sup>-</sup>, CD3<sup>+</sup>, CD2<sup>+</sup>, CD5<sup>-</sup>, CD4<sup>-</sup>, CD8<sup>-</sup>, CD56<sup>+</sup> phenotype with strong expression of cytotoxic proteins (<a href=\"image.htm?imageKey=DERM%2F109198\" class=\"graphic graphic_picture graphicRef109198 \">picture 3</a>). PCGD-TCL has usually an aggressive clinical course, is resistant to multiagent chemotherapy, and has a poor prognosis. (See <a href=\"#H3215520080\" class=\"local\">'Primary cutaneous gamma-delta T cell lymphoma'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary cutaneous CD8<sup>+</sup> aggressive epidermotropic cytotoxic T cell lymphoma (AECTCL) is a rare cutaneous lymphoma characterized by a proliferation of epidermotropic CD8<sup>+</sup> cytotoxic T cells, an aggressive clinical behavior, and poor prognosis. It typically presents with localized or disseminated eruptive papules, nodules, and tumors showing central ulceration and necrosis (<a href=\"image.htm?imageKey=DERM%2F109201\" class=\"graphic graphic_picture graphicRef109201 \">picture 5</a>). The neoplastic T cells show a beta-F1<sup>+</sup>, CD3<sup>+</sup>, CD8<sup>+</sup>, granzyme B<sup>+</sup>, perforin<sup>+</sup>, TIA-1<sup>+</sup>, CD45RA<sup><span class=\"nowrap\">+/-</sup>,</span> CD45RO<sup>-</sup>, CD2<sup><span class=\"nowrap\">-/+</sup>,</span> CD4<sup>-</sup>, CD5<sup>-</sup>, CD7<sup><span class=\"nowrap\">+/-</sup></span> phenotype (<a href=\"image.htm?imageKey=DERM%2F109207\" class=\"graphic graphic_picture graphicRef109207 \">picture 7</a>). The clinical course is aggressive, and the response to chemotherapy is often disappointing. (See <a href=\"#H3966910172\" class=\"local\">'Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T cell lymphoma'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary cutaneous acral CD8<sup>+</sup> T cell lymphoma is a newly described entity histologically characterized by a diffuse infiltrate of medium-sized CD8<sup>+</sup> cytotoxic T cells suggesting a high-grade malignant lymphoma and an indolent clinical behavior. The tumor cells have a CD3<sup>+</sup>, CD4<sup>-</sup>, CD8<sup>+</sup>, TIA-1<sup>+</sup>, granzyme B<sup>-</sup>, CD30<sup>-</sup> T cell phenotype (<a href=\"image.htm?imageKey=DERM%2F109235\" class=\"graphic graphic_picture graphicRef109235 \">picture 9</a>). Surgical excision or radiotherapy usually result in complete remission. (See <a href=\"#H646240243\" class=\"local\">'Primary cutaneous acral CD8+ T cell lymphoma'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary cutaneous CD4<sup>+</sup> <span class=\"nowrap\">small/medium</span> T cell lymphoproliferative disorder is included as a provisional entity in the 2016 revision of the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissue. It includes (or it is a new term for) both primary cutaneous CD4<sup>+</sup> <span class=\"nowrap\">small/medium</span> T cell lymphoma presenting with a solitary lesion (from the 2005 WHO-European Organization for Research and Treatment of Cancer and 2008 WHO classifications), and idiopathic cutaneous T cell pseudolymphoma with a nodular growth pattern. It presents with a solitary plaque or tumor, generally on the face, the neck, or the upper trunk (<a href=\"image.htm?imageKey=DERM%2F103522\" class=\"graphic graphic_picture graphicRef103522 \">picture 11</a>). It is histologically characterized by a predominance of small to medium-sized CD3<sup>+</sup>, CD4<sup>+</sup>, and CD8<sup>-</sup> T cells; the presence of scattered, large CD3<sup>+</sup>, CD4<sup>+</sup>, PD-1<sup>+</sup> T cells; and an abundant inflammatory infiltrate of small reactive CD8<sup>+</sup> T cells, B cells, and histiocytes. Lesions may resolve spontaneously. Persistent lesions can be treated with intralesional corticosteroids or surgical excision. (See <a href=\"#H622037723\" class=\"local\">'Primary cutaneous CD4+ small/medium T cell lymphoproliferative disorder'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/1\" class=\"nounderline abstract_t\">Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/2\" class=\"nounderline abstract_t\">Tan SH, Sim CS, Ong BH. Cutaneous lymphomas other than mycosis fungoides in Singapore: a clinicopathological analysis using recent classification systems. Br J Dermatol 2003; 149:542.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/3\" class=\"nounderline abstract_t\">Park JH, Shin HT, Lee DY, et al. World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphoma in Korea: a retrospective study at a single tertiary institution. J Am Acad Dermatol 2012; 67:1200.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/4\" class=\"nounderline abstract_t\">Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/5\" class=\"nounderline abstract_t\">Guitart J, Weisenburger DD, Subtil A, et al. Cutaneous &gamma;&delta; T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. Am J Surg Pathol 2012; 36:1656.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/6\" class=\"nounderline abstract_t\">Tripodo C, Iannitto E, Florena AM, et al. Gamma-delta T-cell lymphomas. Nat Rev Clin Oncol 2009; 6:707.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/7\" class=\"nounderline abstract_t\">Swerdlow SH, Jaffe ES, Brousset P, et al. Cytotoxic T-cell and NK-cell lymphomas: current questions and controversies. Am J Surg Pathol 2014; 38:e60.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/8\" class=\"nounderline abstract_t\">Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 2008; 111:838.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/9\" class=\"nounderline abstract_t\">Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 2003; 101:3407.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/10\" class=\"nounderline abstract_t\">Garcia-Herrera A, Song JY, Chuang SS, et al. Nonhepatosplenic &gamma;&delta; T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation. Am J Surg Pathol 2011; 35:1214.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/11\" class=\"nounderline abstract_t\">Rodr&iacute;guez-Pinilla SM, Ortiz-Romero PL, Monsalvez V, et al. TCR-&gamma; expression in primary cutaneous T-cell lymphomas. Am J Surg Pathol 2013; 37:375.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/12\" class=\"nounderline abstract_t\">Barzilai A, Goldberg I, Shibi R, et al. Mycosis fungoides expressing gamma/delta T-cell receptors. J Am Acad Dermatol 1996; 34:301.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/13\" class=\"nounderline abstract_t\">Magro CM, Wang X. Indolent primary cutaneous &gamma;/&delta; T-cell lymphoma localized to the subcutaneous panniculus and its association with atypical lymphocytic lobular panniculitis. Am J Clin Pathol 2012; 138:50.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/14\" class=\"nounderline abstract_t\">Endly DC, Weenig RH, Peters MS, et al. Indolent course of cutaneous gamma-delta T-cell lymphoma. J Cutan Pathol 2013; 40:896.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/15\" class=\"nounderline abstract_t\">Berti E, Tomasini D, Vermeer MH, et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol 1999; 155:483.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/16\" class=\"nounderline abstract_t\">Santucci M, Pimpinelli N, Massi D, et al. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer 2003; 97:610.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/17\" class=\"nounderline abstract_t\">Robson A, Assaf C, Bagot M, et al. Aggressive epidermotropic cutaneous CD8+ lymphoma: a cutaneous lymphoma with distinct clinical and pathological features. Report of an EORTC Cutaneous Lymphoma Task Force Workshop. Histopathology 2015; 67:425.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/18\" class=\"nounderline abstract_t\">Agnarsson BA, Vonderheid EC, Kadin ME. Cutaneous T cell lymphoma with suppressor/cytotoxic (CD8) phenotype: identification of rapidly progressive and chronic subtypes. J Am Acad Dermatol 1990; 22:569.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/19\" class=\"nounderline abstract_t\">Quintanilla-Martinez L, Jansen PM, Kinney MC, et al. Non-mycosis fungoides cutaneous T-cell lymphomas: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol 2013; 139:491.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/20\" class=\"nounderline abstract_t\">Bekkenk MW, Vermeer MH, Jansen PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood 2003; 102:2213.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/21\" class=\"nounderline abstract_t\">Willemze R. CD30-Negative Cutaneous T-Cell Lymphomas Other than Mycosis Fungoides. Surg Pathol Clin 2014; 7:229.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/22\" class=\"nounderline abstract_t\">Saggini A, Gulia A, Argenyi Z, et al. A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases. Am J Surg Pathol 2010; 34:1168.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/23\" class=\"nounderline abstract_t\">Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95:3653.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/24\" class=\"nounderline abstract_t\">Massone C, Crisman G, Kerl H, Cerroni L. The prognosis of early mycosis fungoides is not influenced by phenotype and T-cell clonality. Br J Dermatol 2008; 159:881.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/25\" class=\"nounderline abstract_t\">Haghighi B, Smoller BR, LeBoit PE, et al. Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study. Mod Pathol 2000; 13:502.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/26\" class=\"nounderline abstract_t\">Mourtzinos N, Puri PK, Wang G, Liu ML. CD4/CD8 double negative pagetoid reticulosis: a case report and literature review. J Cutan Pathol 2010; 37:491.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/27\" class=\"nounderline abstract_t\">Petrella T, Maubec E, Cornillet-Lefebvre P, et al. Indolent CD8-positive lymphoid proliferation of the ear: a distinct primary cutaneous T-cell lymphoma? Am J Surg Pathol 2007; 31:1887.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/28\" class=\"nounderline abstract_t\">Swick BL, Baum CL, Venkat AP, Liu V. Indolent CD8+ lymphoid proliferation of the ear: report of two cases and review of the literature. J Cutan Pathol 2011; 38:209.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/29\" class=\"nounderline abstract_t\">Li JY, Guitart J, Pulitzer MP, et al. Multicenter case series of indolent small/medium-sized CD8+ lymphoid proliferations with predilection for the ear and face. Am J Dermatopathol 2014; 36:402.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/30\" class=\"nounderline abstract_t\">Greenblatt D, Ally M, Child F, et al. Indolent CD8(+) lymphoid proliferation of acral sites: a clinicopathologic study of six patients with some atypical features. J Cutan Pathol 2013; 40:248.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/31\" class=\"nounderline abstract_t\">Kluk J, Kai A, Koch D, et al. Indolent CD8-positive lymphoid proliferation of acral sites: three further cases of a rare entity and an update on a unique patient. J Cutan Pathol 2016; 43:125.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/32\" class=\"nounderline abstract_t\">Beltraminelli H, M&uuml;llegger R, Cerroni L. Indolent CD8+ lymphoid proliferation of the ear: a phenotypic variant of the small-medium pleomorphic cutaneous T-cell lymphoma? J Cutan Pathol 2010; 37:81.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/33\" class=\"nounderline abstract_t\">Wobser M, Roth S, Reinartz T, et al. CD68 expression is a discriminative feature of indolent cutaneous CD8-positive lymphoid proliferation and distinguishes this lymphoma subtype from other CD8-positive cutaneous lymphomas. Br J Dermatol 2015; 172:1573.</a></li><li class=\"breakAll\">Swerdlow A, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Hematopoietic and Lymphoid Tissue, International Agency for Research on Cancer Press, Lyon 2008.</li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/35\" class=\"nounderline abstract_t\">Beltraminelli H, Leinweber B, Kerl H, Cerroni L. Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases. Am J Dermatopathol 2009; 31:317.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/36\" class=\"nounderline abstract_t\">Cetin&ouml;zman F, Jansen PM, Willemze R. Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma. Am J Surg Pathol 2012; 36:109.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/37\" class=\"nounderline abstract_t\">Rijlaarsdam JU, Scheffer E, Meijer CJ, Willemze R. Cutaneous pseudo-T-cell lymphomas. A clinicopathologic study of 20 patients. Cancer 1992; 69:717.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/38\" class=\"nounderline abstract_t\">Grogg KL, Jung S, Erickson LA, et al. Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior. Mod Pathol 2008; 21:708.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/39\" class=\"nounderline abstract_t\">Garcia-Herrera A, Colomo L, Cam&oacute;s M, et al. Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome. J Clin Oncol 2008; 26:3364.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/40\" class=\"nounderline abstract_t\">Rodr&iacute;guez Pinilla SM, Roncador G, Rodr&iacute;guez-Peralto JL, et al. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers. Am J Surg Pathol 2009; 33:81.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/41\" class=\"nounderline abstract_t\">James E, Sokhn JG, Gibson JF, et al. CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature. Leuk Lymphoma 2015; 56:951.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes/abstract/42\" class=\"nounderline abstract_t\">Bakels V, van Oostveen JW, van der Putte SC, et al. Immunophenotyping and gene rearrangement analysis provide additional criteria to differentiate between cutaneous T-cell lymphomas and pseudo-T-cell lymphomas. Am J Pathol 1997; 150:1941.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 103306 Version 4.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1566918739\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1060059838\" id=\"outline-link-H1060059838\">INTRODUCTION</a></li><li><a href=\"#H3215520080\" id=\"outline-link-H3215520080\">PRIMARY CUTANEOUS GAMMA-DELTA T CELL LYMPHOMA</a><ul><li><a href=\"#H977111405\" id=\"outline-link-H977111405\">Epidemiology</a></li><li><a href=\"#H511037125\" id=\"outline-link-H511037125\">Pathogenesis</a></li><li><a href=\"#H2652089255\" id=\"outline-link-H2652089255\">Clinical features</a></li><li><a href=\"#H2462217364\" id=\"outline-link-H2462217364\">Pathology</a><ul><li><a href=\"#H3552705443\" id=\"outline-link-H3552705443\">- Morphology</a></li><li><a href=\"#H4002759965\" id=\"outline-link-H4002759965\">- Immunophenotype</a></li><li><a href=\"#H2076779603\" id=\"outline-link-H2076779603\">- Genetics</a></li></ul></li><li><a href=\"#H3359917847\" id=\"outline-link-H3359917847\">Diagnosis</a></li><li><a href=\"#H615099160\" id=\"outline-link-H615099160\">Differential diagnosis</a><ul><li><a href=\"#H2308806457\" id=\"outline-link-H2308806457\">- Subcutaneous panniculitis-like T cell lymphoma</a></li><li><a href=\"#H1823462876\" id=\"outline-link-H1823462876\">- Mycosis fungoides</a></li></ul></li><li><a href=\"#H2930919974\" id=\"outline-link-H2930919974\">Treatment and prognosis</a></li></ul></li><li><a href=\"#H3966910172\" id=\"outline-link-H3966910172\">PRIMARY CUTANEOUS CD8+ AGGRESSIVE EPIDERMOTROPIC CYTOTOXIC T CELL LYMPHOMA</a><ul><li><a href=\"#H286944658\" id=\"outline-link-H286944658\">Epidemiology</a></li><li><a href=\"#H2670051392\" id=\"outline-link-H2670051392\">Clinical features</a></li><li><a href=\"#H2042083201\" id=\"outline-link-H2042083201\">Pathology</a><ul><li><a href=\"#H340985578\" id=\"outline-link-H340985578\">- Morphology</a></li><li><a href=\"#H459311579\" id=\"outline-link-H459311579\">- Immunophenotype</a></li><li><a href=\"#H3963980722\" id=\"outline-link-H3963980722\">- Genetics</a></li></ul></li><li><a href=\"#H304736455\" id=\"outline-link-H304736455\">Diagnosis</a></li><li><a href=\"#H3129258417\" id=\"outline-link-H3129258417\">Differential diagnosis</a><ul><li><a href=\"#H2956283695\" id=\"outline-link-H2956283695\">- Lymphomatoid papulosis</a></li><li><a href=\"#H227044828\" id=\"outline-link-H227044828\">- Primary cutaneous anaplastic large cell lymphoma</a></li><li><a href=\"#H3313974397\" id=\"outline-link-H3313974397\">- Mycosis fungoides</a></li><li><a href=\"#H2206975216\" id=\"outline-link-H2206975216\">- Pagetoid reticulosis</a></li><li><a href=\"#H339129503\" id=\"outline-link-H339129503\">- Subcutaneous panniculitis-like T cell lymphoma</a></li><li><a href=\"#H3568978086\" id=\"outline-link-H3568978086\">- Primary cutaneous acral CD8+ T cell lymphoma</a></li></ul></li><li><a href=\"#H652721910\" id=\"outline-link-H652721910\">Treatment and prognosis</a></li></ul></li><li><a href=\"#H646240243\" id=\"outline-link-H646240243\">PRIMARY CUTANEOUS ACRAL CD8+ T CELL LYMPHOMA</a><ul><li><a href=\"#H4206581917\" id=\"outline-link-H4206581917\">Epidemiology</a></li><li><a href=\"#H3773574672\" id=\"outline-link-H3773574672\">Clinical features</a></li><li><a href=\"#H1390843739\" id=\"outline-link-H1390843739\">Pathology</a><ul><li><a href=\"#H1613636157\" id=\"outline-link-H1613636157\">- Morphology</a></li><li><a href=\"#H3697945490\" id=\"outline-link-H3697945490\">- Immunophenotype</a></li><li><a href=\"#H1567064775\" id=\"outline-link-H1567064775\">- Genetics</a></li></ul></li><li><a href=\"#H2411723022\" id=\"outline-link-H2411723022\">Diagnosis</a></li><li><a href=\"#H2834565175\" id=\"outline-link-H2834565175\">Differential diagnosis</a></li><li><a href=\"#H2580171248\" id=\"outline-link-H2580171248\">Treatment and prognosis</a></li></ul></li><li><a href=\"#H622037723\" id=\"outline-link-H622037723\">PRIMARY CUTANEOUS CD4+ SMALL/MEDIUM T CELL LYMPHOPROLIFERATIVE DISORDER</a><ul><li><a href=\"#H324713509\" id=\"outline-link-H324713509\">Epidemiology</a></li><li><a href=\"#H3348273444\" id=\"outline-link-H3348273444\">Clinical features</a></li><li><a href=\"#H2139991237\" id=\"outline-link-H2139991237\">Pathologic features</a><ul><li><a href=\"#H1494371565\" id=\"outline-link-H1494371565\">- Morphology</a></li><li><a href=\"#H1865940484\" id=\"outline-link-H1865940484\">- Immunophenotype</a></li><li><a href=\"#H1334410468\" id=\"outline-link-H1334410468\">- Genetics</a></li></ul></li><li><a href=\"#H2031985525\" id=\"outline-link-H2031985525\">Diagnosis</a></li><li><a href=\"#H4285820249\" id=\"outline-link-H4285820249\">Differential diagnosis</a></li><li><a href=\"#H1409425915\" id=\"outline-link-H1409425915\">Treatment and prognosis</a></li></ul></li><li><a href=\"#H1566918739\" id=\"outline-link-H1566918739\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/103306|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/109196\" class=\"graphic graphic_picture\">- Primary cutaneous gamma-delta T cell lymphoma</a></li><li><a href=\"image.htm?imageKey=DERM/109197\" class=\"graphic graphic_picture\">- PCGD-TCL histopathology</a></li><li><a href=\"image.htm?imageKey=DERM/109198\" class=\"graphic graphic_picture\">- PCGD-TCL immunophenotype</a></li><li><a href=\"image.htm?imageKey=HEME/82054\" class=\"graphic graphic_picture\">- SPTCL</a></li><li><a href=\"image.htm?imageKey=DERM/109201\" class=\"graphic graphic_picture\">- CD8+ AECTCL</a></li><li><a href=\"image.htm?imageKey=DERM/109202\" class=\"graphic graphic_picture\">- CD8+ AECTCL histopathology</a></li><li><a href=\"image.htm?imageKey=DERM/109207\" class=\"graphic graphic_picture\">- CD8+ AECTCL immunophenotype</a></li><li><a href=\"image.htm?imageKey=DERM/109234\" class=\"graphic graphic_picture\">- Primary cutaneous acral CD8+ T cell lymphoma</a></li><li><a href=\"image.htm?imageKey=DERM/109235\" class=\"graphic graphic_picture\">- Primary cutaneous acral CD8+ TCL histopathology</a></li><li><a href=\"image.htm?imageKey=DERM/103721\" class=\"graphic graphic_picture\">- B cell pseudolymphoma Borrelia (borrelial lymphocytoma)</a></li><li><a href=\"image.htm?imageKey=DERM/103522\" class=\"graphic graphic_picture\">- CD4+ PCSM-TCL</a></li><li><a href=\"image.htm?imageKey=DERM/103537\" class=\"graphic graphic_picture\">- CD4+ PCSM-TCL histopathology 2</a></li><li><a href=\"image.htm?imageKey=DERM/103538\" class=\"graphic graphic_picture\">- CD4+ PCSM-TCL immunophenotype</a></li></ul></li><li><div id=\"DERM/103306|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/109199\" class=\"graphic graphic_table\">- SPTCL and PCGD-TCL differential</a></li><li><a href=\"image.htm?imageKey=DERM/109206\" class=\"graphic graphic_table\">- CD8+ cutaneous T cell lymphoma differential diagnosis</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-hemophagocytic-lymphohistiocytosis\" class=\"medical medical_review\">Clinical features and diagnosis of hemophagocytic lymphohistiocytosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-extranodal-nk-t-cell-lymphoma-nasal-type\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-mycosis-fungoides\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-peripheral-t-cell-lymphoma-not-otherwise-specified\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-subcutaneous-panniculitis-like-t-cell-lymphoma\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T cell lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-pathologic-features-and-diagnosis-of-sezary-syndrome\" class=\"medical medical_review\">Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-b-cell-pseudolymphomas\" class=\"medical medical_review\">Cutaneous B cell pseudolymphomas</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-t-cell-pseudolymphomas\" class=\"medical medical_review\">Cutaneous T cell pseudolymphomas</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-treatment-of-peripheral-t-cell-lymphoma\" class=\"medical medical_review\">Initial treatment of peripheral T cell lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lymphomatoid-papulosis\" class=\"medical medical_review\">Lymphomatoid papulosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-cutaneous-anaplastic-large-cell-lymphoma\" class=\"medical medical_review\">Primary cutaneous anaplastic large cell lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\" class=\"medical medical_review\">Treatment of relapsed or refractory peripheral T cell lymphoma</a></li></ul></div></div>","javascript":null}